Physician

Richard Y Lee, MD PHD

According to 2025 Medicare claims, Richard Lee, MD PHD (NPI: 1922261718) practices radiation oncology in the Urban Honolulu, HI market, with the plurality of this provider's patient population coming from Honolulu, HI. This provider's primary affiliated billing organization is CANCER CENTER OF HAWAII, LLC (NPI: 1285746636; TIN: 201497111) and primary practice location at 96701-4734.

Lee's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 355 traditional Medicare patients, billed 4,499 HCPCS/CPT codes, and received $602,372 in Medicare payments. The top billing code was G6015 (Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session). Part D data shows 215 prescription claims across 80 beneficiaries totaling $1,571 in drug costs, led by Ciprofloxacin Hcl (Ciprofloxacin Hcl). 2021 DME data shows 22 claims. Open Payments data shows 6 records totaling $166. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $5,171 to $1,571. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	266	4,152	$620,636
2016	304	4,145	$585,839
2017	326	3,962	$577,135
2018	365	5,201	$690,434
2019	326	4,259	$571,711
2020	357	5,376	$769,542
2021	362	5,095	$771,702
2022	343	4,645	$620,543
2023	345	4,543	$593,497
2024	355	4,499	$602,372

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	43	56	$5,171
2016	36	61	$2,554
2017	33	60	$2,855
2018	48	81	$2,002
2019	63	133	$1,172
2020	60	133	$1,236
2021	74	194	$1,881
2022	53	129	$1,444
2023	73	198	$1,270
2024	80	215	$1,571

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	22	$2,391
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session	136	656	$307
77336	Continuing radiation therapy consultation per week	114	209	$78
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	105	148	$63
77014	Ct guidance for insertion of radiation therapy fields	102	1,083	$49
G6002	Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy	117	616	$29

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ciprofloxacin Hcl	Ciprofloxacin Hcl	68	282	$308
Tamsulosin Hcl	Tamsulosin Hcl	13	810	$283
Cephalexin	Cephalexin	40	78	$161
Lorazepam	Lorazepam	42	42	$78
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	21	96	$62

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$166	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Richard Y. Lee, MD PHD?

Tedicare shows public-source Medicare data for Richard Y. Lee, MD PHD (NPI 1922261718), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard Y. Lee, MD PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Richard Y. Lee, MD PHD?

Richard Y. Lee, MD PHD is linked to CANCER CENTER OF HAWAII, LLC (billing NPI 1285746636) in the available physician profile data.

Does Richard Y. Lee, MD PHD have Open Payments data?

Richard Y. Lee, MD PHD has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.